Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$4.43.

  • Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) rose 65.42% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 53.14%. This contributed to the annual value of -$4.43 for FY2024, which is 732.86% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$4.43, which was down 732.86% from $0.70 recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $0.70 during FY2023, and registered a low of -$13.35 during FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$3.39 (2022), whereas its average is -$2.37.
  • In the last 5 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 120.65% in 2023 and then plummeted by 732.86% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$13.35 in 2021, then surged by 74.61% to -$3.39 in 2022, then soared by 120.65% to $0.70 in 2023, then tumbled by 732.86% to -$4.43 in 2024.